Integra LifeSciences Provides Updated Plans for Its Manufacturing Facility in Braintree, Massachusetts

Core Insights - Integra LifeSciences is focused on restoring patients' lives through innovative treatment pathways and high-quality medical technology [1] - The company plans to restart the manufacture of PriMatrix and SurgiMend at a new facility in Braintree, Massachusetts, instead of the Boston site [2][7] - The new Braintree facility is expected to be operational in the first half of 2026 and will enhance quality systems and process flows [4][7] Manufacturing Transition - Following a third-party audit of the Boston facility, the company reassessed its manufacturing plans and decided to consolidate efforts at the new Braintree site [2][3] - The Braintree facility, located 10 miles from Boston, will provide significant capacity for future growth and is designed to create an attractive workplace for employees [4][7] - Temporary use of the Boston site will support product and process development during the transition to the Braintree facility [8] Commitment to Products - The company remains committed to bringing PriMatrix and SurgiMend back to the market and achieving pre-market approval for SurgiMend PRS in implant-based breast reconstruction [4] - The decision to focus on the Braintree facility is seen as a way to limit execution risk while maintaining a minimal difference in timing compared to restarting in Boston [3]